No Data
eyebright medical technology (beijing) co., ltd. (688050.SH): the crystalline artificial crystalline (PR) product is still in the approval process.
Gelonghui October 16th | Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) stated on the investor interaction platform that the company's intraocular lens artificial lens (PR) product is still in the approval process, not yet certified for listing, and it is inconvenient to disclose the business plan. The company will continue to fully utilize its own technological and academic promotion advantages, as well as the synergies of various business lines, to expand brand influence, enhance recognition at the level of doctors, patients, and consumers, continuously consolidate and increase market share.
Eyebright Medical Technology (Beijing) Co., Ltd.'s semi-annual report for 2024
688050 eyebright medical technology (beijing) co., ltd. Summary of semi-annual report for the year 2024
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): The net income for the first half of the year was 0.208 billion yuan, an increase of 27.49% year-on-year.
On August 21, Gelonhui announced the 2024 interim report, with a reported revenue of 0.686 billion yuan, a year-on-year increase of 68.54%; a net profit attributable to shareholders of listed companies of 0.208 billion yuan, a year-on-year increase of 27.49%; a net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of 0.199 billion yuan, a year-on-year increase of 29.95%; basic earnings per share of 1.1 yuan. The net profit attributable to shareholders of listed companies increased by 27.49% in the reporting period. The net profit attributable to shareholders of the listed companies after deducting non-recurring gains and losses increased by 29.95% year-on-year.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): Cosmetic products are not the focus of the current business direction.
On August 14th, Gelonhui reported that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) stated on its investor communication platform that cosmetic products are only one of the company's R&D applications, and not the current key business direction. There is currently no large-scale brand promotion plan.
Eyebright medical technology (beijing) co., ltd. (688050.SH): cumulative buyback of 0.075% of the company's shares.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that as of July 31, 2024, the company has repurchased a total of 142,800 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding trading, accounting for 0.075% of the company's total share capital of 189,544,528 shares. The highest purchase price for the repurchase was 147.90 yuan/share, and the lowest purchase price was 134.10 yuan/share, with a total amount of RMB 20,043,605.54 (excluding transaction fees such as stamp duty and commission).
No Data
No Data